Latest Articles
- Inhaled human insulin: Coup or caution?
Inhaled human insulin is a big step forward, but it comes with cautions, concerns, and additional responsibilities.
- We try to walk the line
Whenever we publish a review of a new drug, we run the risk of being perceived as promoting the drug.
- Should beta-blockers be discontinued when a patient is admitted to the hospital with acutely decompensated heart failure?
Hard data on this topic are scant, but the answer depends on the patient’s perfusion status and vital signs.
- Exenatide and pramlintide: New glucose-lowering agents for treating diabetes mellitus
Insulin is not the only hormone that regulates plasma glucose levels. Two new drugs based on native hormones became available in 2005.
- A tropical souvenir not worth picking up
The patient recently returned from a beach resort in Jamaica and now has a painful rash on her foot. What is it?
- Surrogate markers are not ‘one-size-fits-all’
Blood glucose is a good marker of diabetes. Not so with bone density as a marker of osteoporosis.
- When do common symptoms indicate normal pressure hydrocephalus?
The symptoms of normal pressure hydrocephalus—abnormal gait, cognitive impairment, and urinary dysfunction—are common in elderly patients. How can this rare condition be distinguished from other diseases, and how can it be determined if a patient is likely to benefit from a ventriculoperitoneal shunt?
- Diagnosing primary osteoporosis: It’s more than a T score
In the end, the physician—not the machine—diagnoses osteoporosis.
- ERCP: Current uses and less-invasive options
Because ERCP can cause pancreatitis, newer options have replaced it for patients who have a low pretest probability of bile duct stones.